Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORTNYSE:NVRONASDAQ:SILKNASDAQ:UTRS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$31.17-0.1%$28.16$21.97▼$32.33$1.33B1.61337,498 shs536,060 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.37$224.32M0.81789,244 shs753,602 shsSILKSilk Road Medical$27.49$27.31$6.08▼$27.51$1.12B1.531.20 million shsN/AUTRSMinerva Surgical$0.00$0.00▼$0.00$1K3.67259 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion+0.00%+1.09%+5.38%+26.48%+21.52%NVRONevro0.00%0.00%0.00%+0.02%-30.57%SILKSilk Road Medical0.00%0.00%0.00%0.00%+1.66%UTRSMinerva Surgical0.00%0.00%0.00%0.00%-99.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORTArtivion2.3894 of 5 stars1.64.00.00.02.72.51.9NVRONevro0.1753 of 5 stars1.00.00.00.00.01.70.6SILKSilk Road Medical0.3961 of 5 stars0.80.00.04.30.00.00.6UTRSMinerva SurgicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 3.14Buy$32.002.66% UpsideNVRONevro 1.92Reduce$5.36-8.29% DownsideSILKSilk Road Medical 1.50Reduce$27.500.04% UpsideUTRSMinerva Surgical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AORT, SILK, UTRS, and NVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025AORTArtivionCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.005/6/2025AORTArtivionCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025AORTArtivionJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.005/6/2025AORTArtivionNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$388.54M3.43$0.83 per share37.38$6.59 per share4.73NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72SILKSilk Road Medical$177.13M6.31N/AN/A$3.88 per share7.09UTRSMinerva Surgical$51.69M0.00N/AN/AN/ANaNCompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion-$13.36M-$0.50N/A62.34N/A-5.49%3.63%1.34%8/6/2025 (Estimated)NVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)SILKSilk Road Medical-$55.74M-$1.37N/AN/AN/A-29.53%-37.30%-21.57%N/AUTRSMinerva Surgical-$34.11MN/A0.00N/AN/AN/AN/AN/AN/ALatest AORT, SILK, UTRS, and NVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025AORTArtivion$0.12$0.06-$0.06-$0.01$94.81 million$98.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/ASILKSilk Road MedicalN/AN/AN/AN/AN/AUTRSMinerva SurgicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion1.085.533.95NVRONevro0.675.023.76SILKSilk Road Medical0.497.636.69UTRSMinerva SurgicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%NVRONevro95.52%SILKSilk Road MedicalN/AUTRSMinerva SurgicalN/AInsider OwnershipCompanyInsider OwnershipAORTArtivion8.10%NVRONevro3.20%SILKSilk Road Medical3.90%UTRSMinerva Surgical8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,60042.70 million39.24 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionableSILKSilk Road Medical41040.63 million37.91 millionOptionableUTRSMinerva Surgical1608.88 million8.12 millionNot OptionableAORT, SILK, UTRS, and NVRO HeadlinesRecent News About These CompaniesMinerva Surgical Inc.January 10, 2024 | thestreet.comWhy Is Minerva Surgical (UTRS) Stock Down 50% Today?December 18, 2023 | markets.businessinsider.comMinerva Surgical Inc UTRSDecember 17, 2023 | morningstar.comMMinerva Surgical, Inc.: Minerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finanznachrichten.deMinerva Surgical GAAP EPS of -$0.81 misses by $0.27, revenue of $12M misses by $1.93MNovember 14, 2023 | msn.comMinerva Surgical Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | finance.yahoo.comAccelmed Files Transaction Statement on Schedule 13E-3 with Securities and Exchange CommissionSeptember 29, 2023 | finance.yahoo.comMinerva Surgical Inc (UTRS) Becoming More Attractive for InvestorsSeptember 27, 2023 | knoxdaily.comKUTRS Shares Experience Surge in ValueAugust 25, 2023 | knoxdaily.comKMinerva Surgical Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | finance.yahoo.comMinerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue EstimatesAugust 3, 2023 | finance.yahoo.comInvestors in Minerva Surgical (NASDAQ:UTRS) from a year ago are still down 86%, even after 51% gain this past weekMay 25, 2023 | finance.yahoo.comPatent Grant Sends Healthcare Shares Soaring PremarketMay 24, 2023 | theglobeandmail.comWhy Minerva Surgical Shares Are Taking Off WednesdayMay 24, 2023 | msn.comWhy Is Minerva Surgical (UTRS) Stock Up 229% Today?May 24, 2023 | msn.comQ1 2023 Minerva Surgical Inc Earnings CallMay 3, 2023 | finance.yahoo.comMinerva Surgical Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comModified Minerva orthosis proven helpful in pediatric patients following airway surgeryMay 2, 2023 | medicalxpress.comMMinerva Surgical to Announce First Quarter 2023 Financial ResultsApril 18, 2023 | finance.yahoo.comMinerva Surgical, Inc. (NASDAQ:UTRS) Q4 2022 Earnings Call TranscriptMarch 24, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAORT, SILK, UTRS, and NVRO Company DescriptionsArtivion NYSE:AORT$31.17 -0.02 (-0.06%) As of 06/30/2025 03:58 PM EasternArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Nevro NYSE:NVRO$5.85 +0.01 (+0.10%) Closing price 04/2/2025Extended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Silk Road Medical NASDAQ:SILKSilk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.Minerva Surgical NASDAQ:UTRSMinerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
